Related Experiment Video
Updated: Aug 2, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Persistent SARS-CoV-2 Infection in a Multiple Sclerosis Patient on Ocrelizumab: A Case Report
Raghava S Ambadapoodi1, Forest W Arnold2, Julia H Chariker3
1Department of Neurology, University of Chicago Medical Center, Chicago, IL.
Abstract:
A 44-year-old female patient with multiple sclerosis (MS) treated with ocrelizumab was hospitalized with SARS-CoV-2 pneumonia three times over the course of five months, eventually expiring. Viral sequencing of samples from her first and last admissions suggests a single persistent SARS-CoV-2 infection. We hypothesize that her immunocompromised state, due to MS treatment with an immunosuppressive monoclonal antibody, prevented her from achieving viral clearance.
Insights
A patient with multiple sclerosis (MS) on immunosuppressive therapy experienced persistent SARS-CoV-2 pneumonia. This case suggests that B-cell depletion therapy may impair viral clearance, leading to prolonged infections.
Area of Science:
- Immunology
- Infectious Diseases
- Neurology
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Ocrelizumab is an immunosuppressive monoclonal antibody used for MS treatment, targeting B cells.
- Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection can cause pneumonia, posing risks to immunocompromised individuals.
Approach:
- Case study of a 44-year-old female patient with MS treated with ocrelizumab.
- Analysis of three hospitalizations for SARS-CoV-2 pneumonia over five months.
- Viral sequencing from initial and final admissions to investigate infection persistence.
Key Points:
- The patient suffered recurrent SARS-CoV-2 pneumonia despite treatment.
- Viral sequencing indicated a single, persistent SARS-CoV-2 infection.
- Immunosuppression from ocrelizumab is hypothesized to impede viral clearance.
Conclusions:
- Persistent SARS-CoV-2 infection can occur in immunocompromised MS patients.
- B-cell depletion therapy may compromise the immune system's ability to clear viral infections.
- This case highlights potential risks associated with immunosuppressive treatments during viral pandemics.
More Related Videos
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Treatment Resistant Cancers
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

